#Medical AI #iMedImage #Diagens

Diagens Annual Results: A Transformative Year in Medical AI

Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526), a leading innovator in medical imaging technology, has recently released its first annual report since going public. This pivotal moment showcases the company's remarkable growth and its transition from technical validation to large-scale commercialization. With annual revenue hitting RMB 164 million, representing a staggering 133.7% increase year-over-year, Diagens solidifies its presence in the medical AI landscape.

The Rise of iMedImage®: Transforming Medical Imaging

At the heart of this transformative year is Diagens’ proprietary iMedImage® foundation model, a groundbreaking technology that has redefined medical imaging capabilities. In the last fiscal year, the company reported a staggering 331.7% surge in technology licensing revenue, which reached RMB 84.34 million, firmly establishing it as the primary driver of Diagens' growth. The company also recorded a gross profit of RMB 118 million and an impressive gross margin of 71.8%, highlighting its sustainable and lucrative business model centered on the 'Model-as-a-Service' (MaaS) approach.

Addressing the Limitations of Traditional AI

Traditionally, the medical imaging sector has faced challenges with 'point solutions,' where AI models are developed for single diseases in various modalities, resulting in lengthy development cycles and high costs. Diagens aims to disrupt this antiquated paradigm with its iMedImage® model, which boasts an impressive 104 billion parameters and covers 19 imaging modalities and 26 clinical specialties.

This standardized technological foundation significantly reduces the cost and time required for developing specialized models—by more than 90%. Diagens is not just improving efficiency; it's transforming the very capabilities of clinical diagnosis and treatment.

“A systemic restructuring of clinical capabilities is underway,” said a representative of Diagens' expert team, composed of veterans from various disciplines, including basic medicine, clinical practice, and AI development. “Our mission is to bridge the cost-efficiency gap in medical AI, transitioning from 'craftsman-style' development to an industrial-scale deployment that addresses the pressing global healthcare resource gaps.”

The MaaS Ecosystem: Scaling AI in Healthcare

In addition to its technological advancements, Diagens has launched the iMed MaaS® platform, which, in just six months, has partnered with 65 leading hospitals, resulting in the incubation of 92 specialized AI models. This ecosystem uniquely enables healthcare institutions to swiftly deploy AI capabilities tailored to specific clinical needs, thereby turning intricate diagnostic skills into a scalable and accessible utility.

Currently, Diagens has extended its reach to over 400 medical institutions across China, including a remarkable adoption rate among 40% of the nation's top ten hospitals. Beyond national borders, the company is setting its sights on becoming a global provider of healthcare AI infrastructure, with the aim of democratizing access to high-quality diagnostics worldwide.

Strategic Vision for the Future

Looking ahead, Diagens is committed to enhancing its collaborations with ecosystem partners, including tech giants like Tencent, to develop a comprehensive hub of